Orgenus Pharma, 105 College Road East, second floor, Princeton 08540; 609-297-2121; fax, 609-297-2120. Satish Srinivasan, VP business development and operations. www.orchidpharma.com.
Orgenus Pharma moved from 700 Alexander Park to 105 College Road East at the end of March. The company, founded in 2006, is a subsidiary of Orchid Chemicals & Pharmaceuticals Ltd.
Century 21 Abrams Hutchinson Associates, 3562 Route 27, Suite 112, Kendall Park 08824; 609-750-7300; fax, 609-275-1099. Gloria Hutchinson, co-owner. www.century21ah.com.
Century 21 Realty has moved its Plainsboro office to Route 27. Century 21 co-owner Gloria Hutchinson said the shopping center where it had been located for 10 years had been experienced slowing business, and that the location was close to the recently opened Century 21 West Windsor office.
Northwest Criterion Asset Management LLC, 914 Commons Way, Princeton 08542; 609-924-4488; fax, 609-924-1155. Michael A. Camp, principal. www.nwcriterion.com.
Northwest Criterion Management, an investment advisement firm, has moved from 34 Chambers Street to 914 Commons Way in Montgomery Commons.
Raging Capital Management , 10 Princeton Avenue, Rocky Hill 08553; 609-357-1870.
Hedge fund company Raging Capital Management has moved from its former Witherspoon Street headquarters to a larger office on Princeton Road in Rocky Hill.
Derma Sciences Inc. (DSCIOB), 214 Carnegie Center, Suite 300, Princeton 08540; 609-514-4744; fax, 609-514-0502. Edward J. Quilty, CEO. www.dermasciences.com.
Derma Sciences, a medical device and pharmaceutical company, has signed a five-year exclusive global rights agreement with New Cast Industries of South Korea.
The agreement concerns the casting element in the TCC-EZ — a casting system to aid the healing of diabetic foot ulcers. According to a company release, Derma plans to begin sales of the system in markets throughout Europe, the Middle East, Asia and Latin America, pending regional regulatory approvals — potentially as early as this summer in some instances.
Under the agreement, New Cast will supply product to Derma Sciences at a discounted rate. The agreement expands the company’s existing agreement with New Cast that covers sales in North America.
“TCC-EZ has become an anchor product in our advanced wound care product portfolio with a current sales run rate of $8.5 million in the U.S. alone,” said Barry Wolfenson, president of Derma’s Advanced Wound Care and Pharmaceutical Development group. “We are very pleased with the pace of domestic sales growth, and expect that TCC-EZ will be embraced by patients and practitioners around the world in treating diabetic foot ulcers.”
The TCC-EZ became part of Derma’s product line when it acquired MedEfficiency last April. Derma paid $14.5 million for the privately held company.